Single-Dose BTK Inhibitor Regimen for Immune Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immune system diseases, such as autoimmune diseases and skin allergy disorders, lack effective and safe BTK inhibitors that can be administered in a single dose.
Innovation Solution
A highly selective irreversible BTK inhibitor represented by Formula (I) or its stereoisomers, tautomers, solvates, or pharmaceutically acceptable salts, which are used in a single-dose medicament to treat and/or prevent immune system diseases, offering high enzyme activity, good water solubility, low human plasma protein binding, and long oral half-life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current BTK inhibitors are used for treating immune system diseases, then therapeutic effect is achieved, but patient compliance is poor due to requiring multiple doses
Solution Approach 1:
The patent applies periodic action by designing a dosing regimen that transitions from frequent administration to less frequent administration. The BTK inhibitor is administered initially at frequent intervals to achieve rapid target occupancy, then maintenance dosing at extended intervals (e.g., once weekly or monthly) sustains therapeutic effect, improving patient compliance while maintaining reliability
Solution Approach 2:
The patent applies preliminary action through a loading dose strategy where a higher initial dose or multiple initial doses are administered to rapidly achieve effective BTK inhibition and target occupancy before transitioning to lower maintenance doses. This preliminary aggressive treatment ensures rapid therapeutic effect establishment
2Reliability
If higher doses of BTK inhibitor are administered to ensure therapeutic effect, then efficacy is improved, but safety window decreases
Solution Approach 1:
The patent applies dynamics by implementing a dynamic dosing regimen that adjusts the dose amount and frequency based on the treatment phase. Initial loading doses may be higher to rapidly achieve efficacy, then maintenance doses are reduced to sustain therapeutic effect while minimizing toxicity. The dosing schedule is dynamically adapted to balance efficacy and safety window throughout treatment
Solution Approach 2:
The patent applies feedback mechanisms where patient response, BTK target occupancy levels, and safety parameters are monitored to adjust dosing. Therapeutic drug monitoring and assessment of clinical response guide dose modifications, ensuring efficacy is maintained while avoiding excessive dosing that would narrow the safety window
3Reliability
If BTK inhibitor is administered frequently to maintain therapeutic levels, then continuous efficacy is achieved, but loss of time for patients increases
Solution Approach 1:
The patent applies periodic action by extending the dosing interval from frequent administration (e.g., daily or weekly) to less frequent administration (e.g., once monthly or quarterly) while maintaining continuous therapeutic effect. This is achieved through sustained-release formulations, long-acting injectable forms, or accumulation of drug in target tissues that prolongs effective inhibition, reducing patient visit frequency while maintaining continuous efficacy
Data Source
AI summary
Provided is use of a compound represented by Formula (I), or a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt of the compound represented by Formula (I) in the manufacture of a medicament for treating and/or preventing an immune system disease.